Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 56Terminated 9Active not recruiting 3Withdrawn 2Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 7Leukemia 4Multiple Myeloma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hematologic Diseases 1Hemangiosarcoma 1Castrate-resistant Metastatic Prostate Cancer 1Blast Crisis 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00972101 2012-10-11

Infusion of Expanded Cord Blood T Cells

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡